Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04762680
Previous Study | Return to List | Next Study

Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04762680
Recruitment Status : Recruiting
First Posted : February 21, 2021
Last Update Posted : February 24, 2021
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Brief Summary:

The primary objectives of the study are:

  • To assess the safety profile of all participants in each age group and in each study intervention group.
  • To assess the neutralizing antibody profile 14 days after the last vaccination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naïve adults in each study intervention group.

The secondary objectives of the study are:

  • To assess the neutralizing antibody profile in SARS-CoV-2 naïve participants at pre-defined time points during the study.
  • To assess the neutralizing antibody profile in SARS-CoV-2 non-naïve participants at pre-defined time points during the study.
  • To assess the binding antibody profile in SARS-CoV-2 naïve and non-naïve participants at pre-defined time points during the study.
  • To describe the occurrences of laboratory-confirmed symptomatic COVID-19 in all participants in each study intervention group.
  • To describe the occurrences of serologically-confirmed SARS-CoV-2 infection in each study intervention group.

Condition or disease Intervention/treatment Phase
COVID-19 (Healthy Volunteers) Biological: SARS-CoV-2 recombinant protein vaccine Formulation 1 Biological: SARS-CoV-2 recombinant protein vaccine Formulation 2 Biological: SARS-CoV-2 recombinant protein vaccine Formulation 3 Phase 2

Detailed Description:
The duration of each participant's participation in the trial will be approximately 365 days post-injection 2 (ie, 386 days total).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 720 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Participants, outcome assessors, Investigators, laboratory personnel, and sponsor trial staff are blinded to intervention group; and those preparing the study interventions are unblinded to vaccine assignment group.
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine With AS03 Adjuvant in Adults 18 Years of Age and Older
Estimated Study Start Date : February 2021
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022

Arm Intervention/treatment
Experimental: SARS-CoV-2 vaccine Formulation 1
2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
Biological: SARS-CoV-2 recombinant protein vaccine Formulation 1
Pharmaceutical form: Emulsion for injection. Route of administration: Intramuscular injection

Experimental: SARS-CoV-2 vaccine Formulation 2
2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
Biological: SARS-CoV-2 recombinant protein vaccine Formulation 2
Pharmaceutical form: Emulsion for injection. Route of administration: Intramuscular injection

Experimental: SARS-CoV-2 vaccine Formulation 3
2 injections of SARS-CoV-2 vaccine Formulation 3 at Day 1 and Day 22
Biological: SARS-CoV-2 recombinant protein vaccine Formulation 3
Pharmaceutical form: Emulsion for injection. Route of administration: Intramuscular injection




Primary Outcome Measures :
  1. Presence of immediate adverse events [ Time Frame: Within 30 minutes after vaccination ]
    Immediate adverse events include unsolicited adverse events occurring within 30 minutes after injection.

  2. Presence of solicited injection site or systemic reactions [ Time Frame: Within 7 days after injection ]
    Injection site reactions: injection site pain, erythema and swelling. Systemic reactions: fever, headache, malaise and myalgia.

  3. Presence of unsolicited adverse events [ Time Frame: Within 21 days after injection ]
    Adverse events other than solicited reactions.

  4. Presence of serious adverse events [ Time Frame: From Day 1 to Day 387 ]
    Serious adverse events are reported throughout the study.

  5. Presence of adverse events of special interest [ Time Frame: From Day 1 to Day 387 ]
    Adverse events of special interest are reported throughout the study.

  6. Presence of medically-attended adverse events [ Time Frame: From Day 1 to Day 387 ]
    Medically-attended adverse events are new onset or a worsening of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department.

  7. Neutralizing antibody titer at Day 1 [ Time Frame: Day 1 ]
    Neutralizing antibody titers are expressed as geometric mean titers.

  8. Neutralizing antibody titer at Day 36 [ Time Frame: Day 36 ]
    Neutralizing antibody titers are expressed as geometric mean titers.

  9. Neutralizing antibody titer fold-rise post-vaccination [ Time Frame: From Day 1 to Day 36 ]
    Neutralizing antibody titer fold-rise post-vaccination.

  10. 2-fold rise and 4-fold-rise in neutralization antibody titer [ Time Frame: From Day 1 to Day 36 ]
    Fold-rise in antibody neutralization titer post-vaccination relative to Day 1.

  11. Responders, as determined by neutralizing antibody titers at Day 36 [ Time Frame: From Day 1 to Day 36 ]
    Responders, defined as participants who had baseline values below lower limit of quantification (LLOQ) with detectable neutralization titer above assay LLOQ at each pre-defined time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titer at Day 36


Secondary Outcome Measures :
  1. Neutralizing antibody titer at all pre-defined time points [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
  2. Neutralizing antibody titer fold-rise post-vaccination at all pre-defined time points [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
    Fold-rise in antibody neutralization titer post-vaccination relative to Day 1.

  3. 2-fold rise and 4-fold-rise in neutralization antibody titer at all pre-defined time points [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
    Fold-rise in antibody neutralization titer post-vaccination relative to Day 1.

  4. Responders, as determined by neutralizing antibody titers at each pre-defined time point [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
    Responders, defined as participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titer at each pre-defined timepoint

  5. Binding antibody concentrations [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
  6. Binding antibody fold-rise [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
    Fold-rise in concentration relative to Day 1.

  7. 2-fold-rise and 4-fold rise in binding antibody concentration [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
    Fold-rise in concentration relative to Day 1.

  8. Responders, as determined by binding antibody concentrations [ Time Frame: Day 1, Day 22, Day 36, Day 78, Day 134, Day 202, Day 292 and Day 387 ]
    Responders are defined as participants who had baseline values below LLOQ with detectable anti-S antibody concentration above assay LLOQ at each pre-defined time point and participants with baseline values above LLOQ with a 4-fold increase in anti-S antibody concentration at each pre-defined time point.

  9. Occurrences of laboratory-confirmed symptomatic COVID-19 [ Time Frame: From Day 1 to Day 387 ]
    Symptomatic COVID-19 is defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Laboratory-confirmed SARS-CoV-2 infection is defined as a positive result for SARS CoV-2 by nucleic acid amplification test (NAAT), done by the central laboratory or locally, on at least one respiratory sample.

  10. Occurrences of symptomatic COVID-19 episodes associated with hospitalization [ Time Frame: From Day 1 to Day 387 ]
    Symptomatic COVID-19 is defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness.

  11. Occurrences of severe symptomatic COVID-19 [ Time Frame: From Day 1 to Day 387 ]
    Symptomatic COVID-19 is defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness with pre-defined criteria of severity.

  12. Occurrences of death associated with symptomatic COVID-19 [ Time Frame: From Day 1 to Day 387 ]
    Symptomatic COVID-19 is defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness.

  13. Occurrences of serologically-confirmed SARS-CoV-2 infection [ Time Frame: From Day 1 to Day 387 ]
    Serologically-confirmed SARS-CoV-2 infection is defined as a positive result in a serum sample for antibodies against SARS-CoV-2.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria :

  • Aged 18 years or older on the day of inclusion.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
  • Is of non-childbearing potential. To be considered of non-childbearing potential, a female mut be post-menopausal for at least 1 year or surgically sterile.

OR

  • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the second vaccination. A subject of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention.
  • Informed consent form has been signed and dated.
  • Able to attend all scheduled visits and to comply with all trial procedures.
  • SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies.
  • For persons living with human immunodeficiency virus (HIV), stable HIV infection determined by participant currently on antiretrovirals with CD4 count > 200/mm3.
  • Does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination to 3 weeks after the second vaccination despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment

Exclusion criteria:

  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances.
  • Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on Investigator or designee's judgment.
  • Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator or designee's judgment.
  • Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator or designee's judgment.
  • Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the trial procedures.
  • Receipt of solid-organ or bone marrow transplants in the past 180 days.
  • Receipt of anti-cancer chemotherapy in the last 90 days.
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A prospective participant should not be included in the trial until the condition has resolved or the febrile event has subsided.
  • Receipt of any vaccine in the 30 days preceding or on the day of the first trial vaccination or planned receipt of any vaccine in the 30 days following the second trial vaccination except for influenza vaccination, which may be received at any time in relation to trial intervention.
  • Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]).
  • Participation at the time of trial enrollment (or in the 30 days preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04762680


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext option 6 Contact-US@sanofi.com

Locations
Layout table for location information
United States, Florida
Investigational Site Number 8400179 Recruiting
Orlando, Florida, United States, 32806
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Pasteur, a Sanofi Company
ClinicalTrials.gov Identifier: NCT04762680    
Other Study ID Numbers: VAT00002
U1111-1251-4616 ( Other Identifier: UTN )
First Posted: February 21, 2021    Key Record Dates
Last Update Posted: February 24, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs